Overview

Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder

Status:
Recruiting

Trial end date:
2021-12-15

Target enrollment:

Participant gender:

Summary

This study is looking to minimize side effects, while maintaining and potentially improving the therapeutic benefit to patients suffering from Female Sexual Arousal Disorder by providing a topical preparation of Sildenafil locally to the vulvar-vaginal tissue.

Phase:

Phase 2

Details

Lead Sponsor:

Strategic Science & Technologies, LLC

Collaborator:

Daré Bioscience, Inc.

Treatments:

Sildenafil Citrate